Details for Patent: 10,695,350

Which drugs does patent 10,695,350 protect, and when does it expire?

Patent 10,695,350 protects IMBRUVICA and is included in three NDAs.

Protection for IMBRUVICA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-six patent family members in fourteen countries.

Summary for Patent: 10,695,350

Title:	Methods of treating and preventing graft versus host disease
Abstract:	Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.
Inventor(s):	Byrd; John C. (Columbus, OH), Dubovsky; Jason A. (Columbus, OH), Muthusamy; Natarajan (Columbus, OH), Johnson; Amy J. (Columbus, OH), Miklos; David (Stanford, CA)
Assignee:	Pharmacyclics LLC (Sunnyvale, CA)
Application Number:	16/582,945
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 10,695,350

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pharmacyclics Llc	IMBRUVICA	ibrutinib	SUSPENSION;ORAL	217003-001	Aug 24, 2022		RX	Yes	Yes						TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY
Pharmacyclics Llc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No					Y
Pharmacyclics Llc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-001	Nov 13, 2013		RX	Yes	Yes					Y
Pharmacyclics Llc	IMBRUVICA	ibrutinib	TABLET;ORAL	210563-001	Feb 16, 2018		RX	Yes	No					Y

International Family Members for US Patent 10,695,350

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	098208
Australia	2014339815
Australia	2020204270
Australia	2022202686